Psoriasis is a chronic autoimmune disease characterized by epidermal hyperproliferation, inflammatory cell infiltration and vascular proliferation in dermis (1), which affects 2% to 3% of the world population (2). A portion of psoriatic patients could develop into psoriatic arthritis, as well as various complications with an increasing risk, such as hyperlipidemia, cardiovascular disease, diabetes, rheumatoid arthritis, and cancer (3–6). Psoriatic patients are generally treated with glucocorticosteroids and/or conventional immunosuppressants, which could temporarily alleviate symptoms, whereas result in serious side effects (7, 8). In recent years, drugs for psoriasis have been screened as target suppression of IL-17A, IL-23, and Janus kinase (JAK), such as ustekinumab, ixekizumab, and tofacitinib, which are well effective but expensive (9–13).
The occurrence of psoriasis is related to various factors, such as genetic and environmental factors, metabolic disorders, and immunity. So far, its exact pathogenesis remains unclear, but it is generally believed that T cell-mediated immunity plays an important role in its development. Meanwhile, the imbalance between the pro-inflammatory Th17 cells and the anti-inflammatory Treg cells has caused a variety of autoimmune diseases, including psoriasis (14). IL-17 produced by Th17 cells has been shown to play a central role in psoriasis, which induces the production of proinflammatory chemokines, cytokines, and antimicrobial peptides in keratinocytes (15). Tumor necrosis factor alpha induced protein 3 (TNFAIP3/A20) and TNFAIP3 interacting protein 1 (TNIP1) have been accepted as the related candidate genes for psoriasis (16–18). Act1 is an essential adaptor molecule in IL-17–mediated signaling which could mediate the lysine-63–linked ubiquitination of tumor necrosis factor receptor-associated factor 6 (TRAF6) as a U-box E3 ubiquitin ligase (19). That is, IL-17 acts through Act1 and TRAF6 to mediate the downstream NF-κB signaling pathway (20).

MicroRNA (miRNA) is a small non-coding RNA molecule in plants, animals, and some viruses containing about 22 nucleotides. It plays a key role in regulating RNA silencing and posttranscriptional gene expression (21). miRNA participates in a variety of biological procedures, and its expression disorders could result in human diseases, such as cancer, inflammations, and immune abnormalities (22, 23). As with psoriasis, miR-155 has been found to be highly expressed in psoriatic and various autoimmune diseases patients. The level of miR-155 in skin has been demonstrated to have a significantly positive correlation with PASI score and IL-17A content (24). Although several miRNAs have been identified as positive or negative regulators in the regulation of psoriasis, the detailed mechanism needs to be further illustrated.

Ebosin, a novel exopolysaccharide composed of rhamnose, fucose, arabinose, mannose, xylose, glucose, galactose, and galacturonic acid, was isolated from the supernatant of the fermentation culture of Streptomyces sp. 139 (25). Previous studies have shown that Ebosin significantly suppresses the development of rat collagen-induced arthritis in vivo (26), and inhibits IL-1β–induced MAPK and NF-κB signaling pathway in rat fibroblast-like synoviocytes (FLSs) in vitro (25). Interestingly, we found that Ebosin could reduce IFNγ-induced CXCL-9 level in HaCaT cells, which is a key evaluated indicator for psoriasis.

In this study, we found that Ebosin could ameliorate psoriatic skin lesions, improve skin immunopathology, and reduce inflammatory factors expression in imiquimod (IMQ)-mediated psoriasis in a mouse model. Combined with our RNA-seq results on LPS-induced inflammatory HaCaT cell models, we concluded that Ebosin is effective on psoriasis through IL-17 signaling pathway and T cells regulation targeted by miR-155.

**MATERIALS AND METHODS**

**Isolation of Ebosin**

Streptomyces sp. 139 producing Ebosin was isolated from a soil sample in China and kept in the China General Microbiology Culture Collection Center (No. 0405). The strain was cultured at 28°C for 96 h in TSB medium supplemented with 5 mM MgCl₂ and 0.5% glycine or fermentation medium. Ebosin was isolated from the supernatant of Streptomyces sp. 139 fermentation culture using the previously described protocol (27).

**Cell Lines and Culture**

The HaCaT and CCC-ESF-1 cell lines were purchased from The National Experimental Cell Resource Sharing Platform (Beijing, China). The cells were cultivated in Minimum Essential Medium with Eagle’s Balanced Salts (MEM-EBSS; HyClone, Solarbio, Beijing, China) containing 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), and were incubated at 37°C with 5% CO₂. Cells were treated with 10 μg/ml lipopolysaccharide (LPS; Beyotime, Shanghai, China) and series concentration of Ebosin for 24 h. Ebosin was prepared as previously described (25) and was stored at −20°C.

**Cell Viability**

HaCaT and CCC-ESF-1 cells were seeded in a 96-well plate at a density of 3×10⁴ cells/ml, and were incubated with Ebosin at concentrations ranging from 0 to 100 μg/ml within 36 h. At the end of exposure, 10 μl MTT (5 mg/ml) was added to each well and cells were incubated at 37°C for 4 h. The media was removed, and 100 μl DMSO was added into each well to dissolve the formazan crystals. Cell viability was detected at 490 nm by Victor X5 multi-label microplate detector (PerkinElmer, MA, USA) and was calculated with a negative control as 100%.

**Experimental Animals**

Imiquimod cream (IMQ, 5%) was obtained from Sichuan Mingxin Pharmaceutical Co., Ltd. (Sichuan, China). Methotrexate (MTX) was obtained from SPH Sine Pharmaceutical Laboratories Co., Ltd. (Shanghai, China). Male BALB/c mice of bodyweight 18 to 22 g were purchased from Beijing HFK Bioscience Co., Ltd, allowed to acclimate to a new SPF surrounding (temperature: 22 ± 2°C, humidity: 40–60%, light/dark cycle: 12 h) for 1 week, with food and water supplied ad libitum. Animal experimental protocols were performed under NO. IMB-20191025(D3) according to the Chinese National Guidelines for the Care and Use of Laboratory Animals and approved by the Animal Experimental Ethics Committee of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College.

**IMQ-Induced Psoriasis-Like Mouse Model and Animal Treatment**

BALB/c mice were randomly divided into six groups, including control group, vehicle group, MTX group (1 mg/kg), Ebosin low-dose group (Ebosin-L, 200 mg/kg), Ebosin medium-dose group (Ebosin-M, 400 mg/kg) and Ebosin high-dose group (Ebosin-H, 800 mg/kg). The back hair of all mice was shaved in an area of 2 cm × 3 cm. All groups except the control group were topically administered with a dose of 62.5 mg IMQ scribbled on the back skin of mice for seven consecutive days. MTX and Ebosin groups were orally administered at a dosage of 1 and 200/400/800 mg/kg/7 days in advance, and for 14 consecutive days respectively. Mice were sacrificed on the seventh day of IMQ-administration, and the skin, spleens were collected for further analyses.
Evaluation of the Severity of Psoriatic Skin Lesion

The thickness of skin was measured by callipers. The severity of skin lesion was evaluated by Psoriasis Area and Severity Index (PASI) scored ranging from 0 to 4, which comprises the parameters of skin erythema, scaling, bulge, and thickness. The value of 0, 1, 2, 3, and 4 represents the severity of none, slight, moderate, marked, and severe, respectively. The average score of each group was calculated to evaluate the severity of psoriatic skin lesion.

Histological Analysis and Immunohistochemistry

Back skin samples of the mice were fixed in 4% neutral paraformaldehyde for 24 h and were then embedded in paraffin. The paraffin block was cut into 3 µm slices. For H&E staining, the slices were stained with 3'-diaminobenzidine (DAB, Sigma-Aldrich) and were counterstained by hematoxylin. For immunohistochemistry staining, slices were incubated with primary monoclonal anti-CD3 (Abcam, ab5690), anti-CD8 (Abcam, ab237723) or anti-Ki67 (Abcam, ab15580) antibody at a dilution of 1:200 at 4°C overnight, then with secondary antibody HPR-anti-Rabbit IgG (CST). The specificity of the primary antibodies was tested by substituting isotype-matched antibodies (Abcam, ab171870 for CD3 and Ki67; Abcam, ab172730 for CD8). Slices were imaged at a magnification of 100×, and the integrated optical density (IOD) of CD3, CD8, and Ki67 was measured using LAS X software (Leica).

Flow Cytometric Analysis

Spleen cells were prepared and stained for surface markers with anti-CD4-FITC (1:100, BD Pharmingen, 557397) and anti-CD25-PerCP-Cy5.5 (1:250, BD Pharmingen, 551071) separately. To determine intracellular Foxp3 and IL-17A expression, cells were fixed and permeated by Transcription Factor Buffer Set (BD Pharmingen, 562574), and were then stained with anti-Foxp3-PE (1:250, BD Pharmingen, 563101) or anti-IL-17A-Alex647 (1:250, BD Pharmingen, 560184). The frequency of CD4+CD25+Foxp3+ Tregs and CD4+IL17A+Th17 cells were finally analyzed through FACSCalibur (BD Biosciences).

Quantitative Real-Time Reverse Transcription PCR (RT-PCR)

Total mRNA was extracted from cells and skin tissues with TRIzol Reagents (Trans, Beijing, China), and was transcribed into cDNA with TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (Trans, Beijing, China) according to the manufacturer’s introduction. The amplification protocol consisted of an initial step of 30 s at 94°C followed by 40 cycles of 5 s at 94°C and 30 s at 60°C on a BioRad CFX96 (BioRad, USA) using PerfectStart Green qPCR SuperMix (Trans, Beijing, China). The relative expression levels were normalized to gapdh level using the 2^−ΔΔCT method. The primer sequences are listed in Table S1.

miRNA Determination

For quantification of various miRNA levels, miRNA was extracted with EasyPure miRNA Kit (Trans, Beijing, China) and was transcribed into cDNA with TransScript miRNA First-Strand cDNA Synthesis SuperMix (Trans, Beijing, China). The amplification of miRNA was performed with the specific primers shown in Table S2 on a BioRad CFX96 (BioRad, USA) under the standard conditions. The relative miRNA levels were determined by normalizing to U6 using the 2^−ΔΔCT method.

Western Blot

Total protein samples in cells and skin tissues were prepared by RIPA buffer on ice-bath for 30 min. The supernatant was collected after centrifugation at 12,000 rpm for 10 min at 4°C, and the protein concentration was measured by BCA protein assay kit (Applygen, Beijing, China). 30 µg protein of each sample was loaded to an 8% SDS-PAGE gel and was transferred to a PVDF membrane. The PVDF membranes were blocked with 5% (w/v) skimmed milk powder in TBST for 2 h, and were subsequently incubated with primary anti-phospho-IKKα/β (#2697, Cell Signaling Technology, Boston, USA), anti-IKKβ (#8943, Cell Signaling Technology, Boston, USA), anti–phospho–IKKβζ (#2859, Cell Signaling Technology, Boston, USA), anti–IkBα (#4812, Cell Signaling Technology, Boston, USA), anti-phospho-NF-kB p65 (#3033, Cell Signaling Technology, Boston, USA), anti-NF-kB p65 (#8242, Cell Signaling Technology, Boston, USA), anti-A20 antibodies (#5630, Cell Signaling Technology, Boston, USA) (1:1000 for CST antibodies) and anti-Act1 (sc-398161, Santa Cruz Biotechnology, CA, USA), anti-TRAF6 antibodies (sc-8409, Santa Cruz Biotechnology, CA, USA) (1:200 for SC antibodies) at 4°C overnight. Then the membranes were washed using TBST and incubated with secondary HRP-conjugated goat anti-rabbit or antimouse IgG antibody (1:10000) for 1 h at room temperature. The blots were detected by an enhanced chemiluminescence method on a Bio-Rad Gel imaging system and were analyzed by Image J software.

Cell Transfection

To detect the effect of miR-155 on HaCaT cells, we synthesized miR-155 mimics and inhibitor through Ribobio Co., Ltd. (Guangzhou, China). HaCaT cells transfection was conducted by Lipofectamine 3000 Reagent (Invitrogen, NY, USA) following the manufacturer’s instruction. The miRNA sequences (5’–3’) used in this procedure were listed as follows. miR-155-3p mimic: CUCCUCAUAUUGCAAUAACA. miR-155-3p inhibitor: UGUUAUGCUAAUUGUAGGAG. After being transfected with miR-155 mimic/inhibitor or a negative control (NC) (50 nmol/L), the cells were incubated at a 37°C and 5% CO2 incubator for 6 h, and were then incubated for 48 h in substituted fresh MEM containing 10% FBS.

Luciferase Reporter tnfαip3 Expression Assay

To measure luciferase activity of tnfαip3, the wild type and mutant 3’ UTR sequence of tnfαip3 were linked in the psiCHECK2 plasmid (Promega). The HaCaT cells were co-transfected with miR-155-3p mimic or NC and tnfαip3-3’ UTR WT or MUT luciferase plasmids by the Lipofectamine 3000 transfection agent in a 96-well plate. Fresh media with 10% FBS
was replaced after 6 h transfection. Luciferin intensity was measured using Dual-Luciferase Reporter Assay System (Promega, WI, USA) after 48 h-incubation by Victor X5 multi-label microplate detector (PerkinElmer, MA, USA).

Statistical Analyses
Data was presented as the mean ± SD of at least three replicants and was analyzed by GraphPad Prism 7 software. One-way ANOVA was applied to statistical comparisons between groups, and $p < 0.05$ was considered to be with significance.

RESULTS
Ebosin Ameliorated LPS-Induced Cell Injury
Ebosin was detected with no cytotoxicity on HaCaT cells ranging from 0 to 100 μg/ml within 36 h (Supplementary Figures S1A, B). qRT-PCR was performed to measure the expression of inflammatory cytokines in HaCaT cells (Figure 1). The mRNA levels of ccl2, ccl20, and mmp13 induced by LPS-stimulation were significantly decreased upon treatment with 10 μg/ml Ebosin. The key phosphorylated proteins on IKK/NF-κB signaling pathway, including phospho IKKα/β, IκBα, and P65, were reduced by Ebosin in HaCaT (Figures 1B, C) and CCC-ESF-1 (Figures 1D, E).

RNA-Seq of HaCaT cells with treatment of LPS with or without Ebosin was carried out. Different expressed genes were exhibited in Table S3, and functions of different expressed genes were analyzed by KEGG (Supplementary Figures S2A, B) and GO (Supplementary Figures S2C, D) enrichment. Considering enrichment score, gene numbers, and p-value, the encoding genes of A20, CC- and CXC-chemokines and various cytokines related to IL-17 signaling pathway were considered to be differently expressed (fold change>2 or fold change<0.5, p-value<0.05).

**FIGURE 1** | Effects of Ebosin on LPS-induced HaCaT and CCC-ESF-1 cells. (A) RT-PCR analyses of genes in HaCaT cells, including ccl-20, ccl-2, and mmp13 (mean ± SD, n = 3). (B, C) Western blotting analyses for proteins on IKK/NF-κB signaling pathway in HaCaT cells. (D, E) Western blotting analyses for proteins on IKK/NF-κB signaling pathway in CCC-ESF-1 cells. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ vs. control; *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ vs. LPS-induced group.
Ebosin Ameliorates Skin Lesion in IMQ-Induced Psoriatic Mice

The model of IMQ-induced psoriasis-like mice was used to evaluate the effect of Ebosin on psoriasis. Compared with no skin lesion and sign of inflammation within the control group, the symptoms of psoriasis-like lesions, like scaling and thickening, were deteriorated after 7-day IMQ treatment in vehicle. As expected, treatment with MTX recovered the overall skin lesion. Excitingly, treatment with Ebosin reduced scaling, thickening, and erythema in a dose-dependent manner (Figure 2A). The dosage of Ebosin did not cause any change on weight, while the skin thickness and PASI were reduced by

FIGURE 2 | Ebosin ameliorates skin lesion in IMQ-induced psoriatic mice. (A) The representatives of photos of dorsal skin in IMQ-induced psoriasis-like mice 7 days after IMQ-treatment without or with Ebosin. (B) The thickness of dorsal skin (mean ± SD, n = 6). (C) The PASI scores of the skin lesion in IMQ-induced psoriasis-like mice (mean ± SD, n = 6). (D) H&E staining of the skin of control or IMQ-induced psoriasis-like mice after treatment without or with Ebosin (scale bar is 50 μm). ***P < 0.001 vs. control; **P < 0.01, ***P < 0.001 vs. IMQ-induced vehicle group.
Ebosin treatment (Figures 2B, C). There were significant psoriatic lesions including epidermal hyperplasia, hyperkeratosis, and acanthosis after IMQ treatment viewed from H&E staining. While the epidermal hyperplasia was significantly alleviated after treatment with Ebosin, high dose of Ebosin exhibited slight advantages with MTX (Figure 2D).

Ebosin Inhibits CD3+ and CD8+ T Cell Infiltration and Epidermal Hyperplasia in Skin of Psoriatic Mice

Psoriasis is an autoimmune disease mainly mediated by CD3+ T cells, and CD8+ T cells are known to accumulate in the epidermis of psoriatic skin (28). Psoriasis-like skin inflammation and epidermal infiltration by CD8+ T cells are some of the earliest and most severe features (29). Here CD3 and CD8 expression in skin samples were detected by immunohistochemical assay (Isotype Control was shown in Supplementary Figure S3). CD3 and CD8 expression were significantly increased after IMQ treatment. In addition, significant decreases of CD3 and CD8 expression were observed in mice treated with MTX, media-dose of Ebosin (Ebosin-M) and high-dose Ebosin (Ebosin-H) compared to the mice of vehicle group (p < 0.01, Figures 3A, B), indicating that Ebosin alleviated CD3+ and CD8+ T cell infiltration in the psoriatic skin.

Ki67, as an indication of cell proliferation, was demonstrated to increase in IMQ-treated mice, and significantly decrease in MTX and Ebosin-M, Ebosin-H groups by immunohistochemical staining (p < 0.01 vs vehicle group, Figure 3C).

Ebosin Modulates CD4+CD25+Foxp3+ Tregs and CD4+IL17A+ Th17 Cells in Psoriatic Mice

To evaluate whether Ebosin alleviate psoriasis by inducing regulatory T cells (Treg), spleen cells were isolated and analyzed using a flow cytometer. As shown in Figure 4, IMQ-treatment significantly decreased the percentage of
CD4⁺Foxp3⁺CD25⁺ regulatory cells compared with control group, and high-dose of Ebosin increased the percentage of Tregs ($p < 0.05$). In addition, CD4⁺IL17A⁺ T cells (Th17) was significantly increased after IMQ treatment and decreased by serial doses of Ebosin (all $p < 0.01$), suggesting that Ebosin hindered the development of Th17 in psoriatic mice. However, there was no significant difference of Tregs and Th17 cells between MTX and vehicle group.

**Ebosin Inhibited the Inflammatory Response and Related Signaling**

The effect of Ebosin on the expression of encoding genes of epidermal differentiation related proteins, cytokines, and chemokines in the skin samples were detected by qRT-PCR. S100A8 and S100A9 are two proteins necessary for normal epidermal differentiation and activation of macrophages (30). Keratin 1 (KRT1) and keratin 10 (KRT10) are key proteins associated with terminal differentiation of keratinocytes. The levels of s100a8, s100a9, and krt1, krt10 were enhanced in vehicle group, and were reduced after administration of MTX and Ebosin (Figure 5A, $p < 0.01$). The levels of il-23, il-22, il-17a, il-6, il-1β, tnfα, and ccl2, ccl20 were significantly increased following IMQ treatment ($p < 0.01$, Figure 5A).

Administration of MTX and Ebosin, especially at high dose, significantly reduced the mRNA levels of encoding genes of cytokines and chemokines mentioned above ($p < 0.05$). More importantly, tnfαip3 and nip1, two key genes regulating NF-κB signaling in psoriasis, were significantly inhibited by IMQ and were recovered by media & high dose Ebosin (Figure 5B, $p < 0.05$).

Ebosin targeting A20 (coded protein of tnfαip3)/NF-κB in IMQ-induced psoriatic mice were further investigated by Western blot analysis of skin samples. As shown in Figure 5C, A20 protein was significantly diminished after being induced by IMQ, and evoked following Ebosin administration. As expected, TRAF6, Act1, phospho p65 expressions were notably increased by IMQ and attenuated by Ebosin in a dose dependent manner, indicating that Ebosin exerts antipsoriatic effects through regulating A20/NF-κB signaling pathway. However, it is still unclear how Ebosin acts with tnfαip3 (A20). Our next focus is on miRNAs.

**Effect of Ebosin on miRNA-155 Targeting tnfαip3**

To give insight into the changes of expression level of various miRNAs in psoriasis, we firstly predicted the conserved miRNAs
with good mirSVR scores (≤−0.1) on tnfai3 mRNA 3’UTR and their proper target sites on miRanda (Table S3). Low mirSVR and high PhastCons make it more stable for combination of miRNA-mRNA and more conserved. Expression of 24 screened miRNAs in HaCaT cells were then detected by qRT-PCR following 24 h treatment with LPS. We found that miR-155 expression was substantially increased in LPS-induced cells (Supplementary Figure S4). To determine whether Ebosin could modulate miR-155 expression, we measured the miR-155 level in vitro and in vivo. As shown in Figures 6A, B, Ebosin was observed to decrease miR-155-3p expression in a dose-dependent manner both in LPS-induced HaCaT cells and in psoriatic mice. To investigate whether miR-155 directly binds to the 3’UTR of tnfai3, it was cloned into a vector containing firefly luciferase reporter gene. Meanwhile, a mutant vector was constructed to eliminate the possible recognition by replacing nine seed nucleotides (TGTTAATGC to ACAATTACG) (Figure 6C). The result showed that the luciferase activity of tnfai3 3’ UTR was reduced (~40%) in the presence of miR-155 mimics (Figure 6C). However, all changes disappeared in cells transfected with the mutant vector. To further validate tnfai3 as a target of miR-155, the expression of A20 was shown to decrease significantly in HaCaT cells transfected with miR-155 mimics, while it was increased in blockage cells transfected with miR-155 inhibitor (Figure 6D). Taken together, these results indicate that tnfai3 is directly targeted by miR-155.
DISCUSSION

Ebosin is a novel exopolysaccharide isolated from metabolites of *Streptomyces* sp. 139. It exhibited *in vivo* inflammatory inhibition on both adjuvant arthritis and type II collagen arthritis rat model. Ebosin effectively reduced inflammation and joint damage through inhibiting proteins expression in MAPK and NF-κB signaling pathways in vitro, followed by production suppression of IL-1, TNFα, MMPs, and CC chemokines (25, 31). Excitingly, Ebosin could significantly suppress the production of CXCL-9 in preliminary experiments (Supplementary Figures S1C, D), which is a key indicator of psoriasis. From these results, we deduced that Ebosin has potential effects on psoriasis. Accordingly, RNA-Seq was conducted on LPS-induced HaCaT cell with or without Ebosin treatment, and it was found that Ebosin could decrease the expression of genes encoding for proteins within IL-17 signaling pathway and various cytokines as well as chemokines (Supplementary Figure S2).

Psoriasis is a multifactorial inflammatory skin disease characterized by keratinocyte hyperproliferation of epidermis, immune cell infiltration and disrupted epidermis barrier function. Driven by the exciting activity of Ebosin in vitro, we investigated the effect of Ebosin in IMQ-induced mice. Our study revealed that Ebosin alleviated IMQ-induced psoriasis-like skin inflammation in vivo. It improved skin thickening, erythema, and dramatically reduced the PASI score. mRNA levels of krt1, krt10, s100a8, and s100a9 related to epidermal differentiation were decreased by Ebosin, indicating that Ebosin could reduce hyperplasia of epidermis by targeting the key cells.

Except for hyperplasia of epidermal cells, immune cell infiltration plays a key role in the occurrence and development of psoriasis. The IMQ-induced psoriasis-like skin inflammation in mice has been found to be mediated via the IL-23/IL-17 axis (32). IL-23 activates Th17 cells through STAT3 pathway and promotes the production of cytokines, such as IL-17, IL-22, and TNF-α, and induces the proliferation of keratinocytes expressing IL-22 receptor (33, 34). Antagonists of IL-23 and IL-17 showed good...
therapeutic effects, which also validate the important role of the IL-23-IL-17 axis in psoriasis pathogenesis (35–38). In addition, CD4+CD25+Foxp3+ Tregs could differentiate into IL-17A-producing Th17 cells in psoriasis and aggravate its symptoms by inducing imbalance of Th17/Treg, activating effecting T cells and immune response in skin (39, 40). Our study revealed that Ebosin alleviated IMQ-induced psoriasis-like skin inflammation in vivo and linked to the balance of Treg/Th17 and IL-17 signaling pathway. Ebosin can reduce Act1, TRAF6, and phosphorylation of p65 in psoriatic mice. Act1 is an important adaptor of IL-17 family members, and its binding protein TRAF6 is ubiquitinated by Act1 to mediate MAPK and NF-κB pathway, leading to the upregulation of cytokines such as IL-23, IL-17, IL-22, IL-6, TNF-α, and CCL-20 (19, 41–43). More importantly, tnfaip3 and tnip1 genes play key roles to regulate NF-κB signaling in psoriasis, and Ebosin can increase the expression of A20, a key player in the negative feedback regulation of NF-kappaB signaling encoded by tnfaip3, which has been reported to attenuate NF-κB signaling pathway by editing the ubiquitination of proximal signaling proteins including TRAF6, MALT1, RIPK1, NEMO, UBCH5C, etc (44). It has been shown that lack of A20 impairs the NF-κB negative feedback loop and endorses PKC and p38 MAPK signaling, inducing expression of IL-17 (45). In this study, Ebosin increased the expression of A20, leading to the negative feedback of regulation of NF-kappaB and accumulation of Th17 cells, preventing IL-17A expression. Thus, it is indicated that Ebosin exerts antipsoriatic effects through regulating A20/NF-κB signaling pathway (Figure 7).

**FIGURE 7** | Schematic of the mechanism underlying the Ebosin inhibition of psoriasis development. Ebosin could decrease miR-155 expression, which is responsible for the regulation of A20, leading to the balance of Treg/Th17 and the decreased secretion of inflammatory cytokines via inactivation of NF-κB.
To further study how Ebosin regulates A20, we focus on the miRNA related psoriasis. MicroRNAs are short noncoding RNAs that could regulate the expression of protein-coding genes at the posttranscriptional level, and several miRNAs have been found effective on keratinocyte and immune cells function in psoriatic patients (46–48). MicroRNA 155 was found to be high expressed in autoimmune disease and was positively correlated with PASI and IL-17A level in psoriatic patients. It was reported that miR-155 level was influenced by transcription factor Foxp3, and its deletion could inhibit the immune response of CD4⁺ and CD8⁺ T cells, leading to the differentiation of Treg and Th17 cells by targeting SOCS1 (49, 50). In this study, miR-155 was found to be varied on LPS-induced HaCaT cells and recovered after Ebosin treatment both in vitro and in vivo. miR-155 was found to act on miRanda (http://www.miranda.org/) and was validated by luciferase assay. The induction and inhibition of miR-155 were recovered after Ebosin treatment both in vitro and in vivo.

**CONCLUSIONS**

Through RNA-Seq of HaCaT cells treated with Ebosin, we found that Ebosin can target the encoding genes of cytokines and IL-17 signaling pathway in epidermic cells. Further research demonstrated that Ebosin can ameliorate psoriatic skin lesions and reduce inflammatory factors expression in vivo. The protective role of Ebosin against inflammation-mediated psoriasis is through miR-155-tnfaip3-IL-17 axis. Compared with MTX, Ebosin significantly increased the percentage of CD4⁺Foxp3⁺CD25⁺ Tregs and decreased CD4⁺IL17A⁺ Th17 cells in psoriatic mice. Based on our results, we propose that Ebosin may act as a promising therapeutic agent against psoriasis via targeting epidermic and T cells.

**REFERENCES**

1. Cem G, Barker J. Pathogenesis and Clinical Features of Psoriasis. *Lancet* (2007) 370:263–71. doi: 10.1016/S0140-6736(07)61128-3
2. Lowes M, Bowcock A, Krueger J. Pathogenesis and Therapy of Psoriasis. *Nature* (2007) 445:866–73. doi: 10.1038/nature05663
3. Ryan C, Kirby B. Psoriasis Is a Systemic Disease With Multiple Cardiovascular and Metabolic Comorbidities. *Dermatol Clin* (2013) 33:41–55. doi: 10.1016/j.dcr.2014.09.004
4. Stoica LE, Patrascu V, Dascalu RC, Ciurea ME. Bullous Pemphigoid Associated With Psoriasis, Breast Cancer and Parkinson’s Disease. *Curr Health Sci J* (2014) 40:62–6. doi: 10.12865/CHSJ.40.01.12
5. Orabi AM, Weitz I, Siegel EL, Siebert S, Savage LJ, Aycin SZ, et al. Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. *J Rheumatol* (2014) 41:2290–4. doi: 10.3899/jrheum.1408878
6. Gutmark-Little I, Shah KN. Obesity and the Metabolic Syndrome in Pediatric Psoriasis. *Clin Dermatol* (2015) 33:305–15. doi: 10.1016/j.clindermatol.2014.12.006
7. Colombo D, Cassano N, Allomare G, Giannetti A, Vena GA. Psoriasis Relapse Evaluation With Week-End Cyclosporine A Treatment: Results of a Randomized, Double-Blind, Multicenter Study. *Int J Immunopathol Pharmacol* (2010) 23:1143–52. doi: 10.1177/039463201002300418
8. Tsilos T, Kyrgidis A, Toulis K. Biologic Therapies for Chronic plaque Psoriasis and Cardiovascular Events. *JAMA* (2011) 306:2095–6. doi: 10.1001/jama.2011.1660
9. Galluzzo M, D’Adamo S, Servoli S, Bianchi L, Chimenti S, Talamonti M. Tofacitinib for the Treatment of Psoriasis. *Expert Opin Pharmacother* (2016) 17:1421–33. doi: 10.1080/14656566.2016.1195812
10. Chirciucoza A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, et al. Tofacitinib for the Treatment of Moderate-to-Severe Psoriasis. *Expert Rev Immunol* (2015) 11:443–55. doi: 10.1586/1744666X.2015.1013534
11. Dyring-Andersen B, Skov L, Zachariae C. Ixekizumab for Treatment of Psoriasis. *Expert Rev Clin Immunol* (2015) 11:435–42. doi: 10.1586/1744666X.2015.1023295
12. Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of Ixekizumab With Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results From Two Phase 3 Randomised Trials. *Lancet* (2015) 386:541–51. doi: 10.1016/s0140-6736(15)60129-8
13. Yeilding N, Sapravy P, Brodmerkel C, Benson J, Plotnick M, Zhou H, et al. Development of the IL-12/23 Antagonist Ustekinumab in Psoriasis: Past,

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Animal Experimental Ethics Committee of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College.

**AUTHOR CONTRIBUTIONS**

WG and FX performed most of the research work. WG drafted the manuscript. ZZ and ZL devoted to ebosin preparation. IX and LB designed the research and revised the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from National Key Research and Development Program of China (2018YFA0902000), National Natural Science Foundation of China (81903632 and 31870059), and The Drug Innovation Major Project (2018ZX09711001-007-003).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.662362/full#supplementary-material
31. Zhang Y, Wang L, Li Y. Ebosin: A Potential Therapeutic Agent for Psoriasis. *Int J Invest Dermatol* (2013) 133:17–26. doi: 10.1038/jid.2012.194

32. Van DK, Peter CM, Griffiths CEM, Reich K, CL, Blauvelt A, et al. Secukinumab Long-Term Safety Experience: A Pooled Analysis of 10 Phase II and III Clinical Studies in Patients With Moderate to Severe Plaque Psoriasis. *J Am Acad Dermatol* (2016) 75:83–98. doi: 10.1016/j.jaad.2016.03.024

33. Crow MJ. Therapeutics: Silencing Psoriasis. *Nature* (2012) 492:58–9. doi: 10.1038/49258a

34. Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. *Annu Rev Med* (2017) 68:255. doi: 10.1146/annurev-med-042915-103905

35. Zhang L, Li Y, Yang X, Wei J, Zhou S. Characterization of Th17 and FoxP3+ T Cells in Psoriatic Patients. *Scand J Immunol* (2016) 83:174–81. doi: 10.1111/sji.12406

36. Rios-Blanco L, Or dovas-Montanes J, Perro M, Naval E, Thiriot A, Alvarez D, et al. Nociceptive Sensory Neurons Drive interleukin-23-mediated Psoriasis Skin Inflammation. *Nature* (2014) 510:157–61. doi: 10.1038/nature13199

37. Kimbark W, Kavanaugh A, Reich K. Interleukin-17A: A Unique Pathway in Immune-Mediated Diseases: Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis. *Immunology* (2014) 141:133–42. doi: 10.1111/imim.12142

38. Zhang L, Li Y, Yang X, Wei J, Zhou S. Characterization of Th17 and FoxP3+ T Cells in Psoriatic Patients. *Scand J Immunol* (2016) 83:174–81. doi: 10.1111/sji.12406

39. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23–IL-17 Immune Axis: From Mechanisms to Therapeutic Testing. *Nat Rev Immunol* (2014) 14:585–600. doi: 10.1038/nri3707

40. Hao JQ. Targeting interleukin-22 in Psoriasis. *Inflammation* (2014) 37:94–9. doi: 10.1016/s17053-9175-y

41. Balwag W, Barnes DH, Johnston A. Cytokines in Psoriasis. *Cytokine* (2015) 73:342–50. doi: 10.1016/j.cytato.2014.12.014

42. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-Function Mutations in TNFAIP3 Leading to A20 Haploinsufficiency Cause an Early-Onset Autoinflammatory Disease. *Nat Genet* (2016) 48:67–73. doi: 10.1038/ng.3459

43. Urbano PC, Aguirre-Gamboa R, Ashikov A, Heeswik BV, Koenen HJ. TNFAIP3 /A20 Acts as Master Switch in Tnfα Blockade-Driven IL-17AExpression. *J Allergy Clin Immunol* (2017) 142:1. doi: 10.1016/j.jaci.2017.11.024

44. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell* (2004) 116:281–97. doi: 10.1016/S0092-8674(04)00045-5

45. Liu X, Dong Y, Chen S, Zhang G, Zhang M, Gong Y, et al. Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling After ST-Elevation Myocardial Infarction. *Cardiology* (2015) 132:233–41. doi: 10.1159/000364709

46. Qu YL, Wang HF, Sun ZQ, Tang Y, Liu K. Up-Regulated mir-155-5p Promotes Cell Proliferation, Invasion and Metastasis in Colorectal Carcinoma. *Int J Exp Pathol* (2015) 86:988

47. He Q, Pi XM, Shi Q, Li JW, YC Y, Chen HX. Expression and Significance of mir-155 in Psoriasis Vulgaris. *J Pract Med* (2016) 32:990–3. doi: 10.3738/cjmip.2015.36

48. Zhang Y, Wang L, Bai L, Jiang R, Li Y. Effect of Ebosin on Modulating Interleukin-1β-Induced Inflammatory Responses in Rat Fibroblast-Like Synoviocytes. *Cell Mol Immunol* (2016) 13:584. doi: 10.3738/cjmip.2015.36

49. Zhang Y, Wang LF, Bai JY, Guan MJ, Li Y. Anti-Inflammatory Effect of Ebosin on Rat Collagen-Induced Arthritis Through Suppression Production of Interferon-β, Interferon-γ and Tumor Necrosis Factor-α. *Eur J Immunol* (2003) 33:477–88. doi: 10.1002/eji.200342012

50. Chen J, Wu J, Li J, Jiang R, Li B. A New IL-1 Receptor Inhibitor 139a: Fermentation, Isolation, Physico-Chemical Properties and Structure. *J Antibiot* (2003) 56:87–90. doi: 10.1093/jjicksc/56.1.019

51. Cheuk S, Wilken M, Blomqvist L, Nylen S, Talme T, Stahle M, et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis. *J Immunol* (2014) 192:3111–20. doi: 10.4049/jimmunol.1302313

52. Stockenhuber K, Hegazy AN, West NR, Illott NE, Powerie F. Foxp3+ T Reg Cells Control Psoriasis Inflammation by Restraining an IFN-γ-driven Cdh8 + T Cell Response. *Exp J Exp Med* (2015) 218:1987–98. doi: 10.1177/00144835172094

53. Ryckman C, Vandal K, Rouele P, Talbot M, Tessler PA. Proinflammatory Activities of S100P: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion. *J Immunol* (2003) 170:3233–42. doi: 10.4049/jimmunol.170.6.3233

54. Zhang Y, Wang L, Li Y. Ebosin: A Potential Therapeutic Agent for Rheumatoid Arthritis and Autoinflammatory Syndromes. *Cell Mol Immunol* (2018) 15:12–4. doi: 10.3738/cjmip.2017.90

55. Van DF, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice is Mediated Via the IL-23/IL-17 Axis. *J Immunol* (2009) 182:5836. doi: 10.4049/jimmunol.0802999

56. Sun Y, Zhang J, Hua R, Zhai T, Li H, Wu P, et al. Paucinflorin Inhibits Skin Lesions in Imiquimod-Induced Psoriasis-Like Mice by Downregulating Inflammation. *Int Immunopharmacol* (2015) 24:392–9. doi: 10.1016/j.intimp.2014.12.032

57. Lee YS, Lee MH, Kim HJ, Won HR, Kim CH. Non-Thermal Atmospheric Plasma Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Through Inhibition of Immune Responses and Up-Regulation of PD-L1 Expression. *Sci Rep* (2017) 7:15564. doi: 10.1038/s41598-017-15725-7

58. Van DK, Peter CM, Griffiths CEM, Reich K, CL, Blauvelt A, et al. Secukinumab Long-Term Safety Experience: A Pooled Analysis of 10 Phase II and III Clinical Studies in Patients With Moderate to Severe Plaque Psoriasis. *J Am Acad Dermatol* (2016) 75:83–98. doi: 10.1016/j.jaad.2016.03.024

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Guo, Xu, Zhuang, Liu, Xie and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.